ALNY — Alnylam Pharmaceuticals, Inc.

Is ALNY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $242.61. The rating moved from Neutral to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

Alnylam Pharmaceuticals combines a differentiated RNAi discovery and delivery platform with commercial experience in oligonucleotide therapeutics. The company benefits from recurring revenues from marketed products, strategic partnerships, and multiple clinical and regulatory catalysts that could drive upside over the coming weeks to months. Macro and sector conditions are currently neutral to mildly constructive for advanced biologic modalities, which supports investor interest, but the name remains sensitive to trial outcomes, reimbursement dynamics, and short-term growth-stock flows. Near-term performance will likely track clinical readouts, commercialization execution, and any news on payer access or manufacturing capacity.

Key factors

  • Established RNA interference (RNAi) platform with proven clinical-stage pipeline and commercial experience in oligonucleotide therapeutics.
  • Commercial products and recurring revenue streams that provide a foundation for reinvestment in R&D and lifecycle expansions.
  • Strategic partnerships and commercialization capabilities that can accelerate market access and global rollouts.
  • Favorable thematic backdrop for advanced biologic modalities and supplier demand (CDMO/CRO) that supports long-term sector interest.
  • Multiple near- to mid-term catalysts from pipeline readouts, label expansions, and potential additional approvals that could re-rate the equity.
  • Market positioning in rare-disease and specialty indications, which can command premium pricing and more predictable uptake patterns.

Risks

  • Clinical or regulatory setbacks for key pipeline programs or follow-on indications that would dent growth expectations.
  • Payer pressure and strategic changes in Medicare Advantage / payer reimbursement dynamics that could limit pricing or access.
  • Concentration risk if a small number of products account for a large portion of revenue; delays or competition could materially impact results.
  • Manufacturing/supply chain capacity constraints for complex oligonucleotide products or increased CDMO costs.
  • Valuation sensitivity in a growth-rotation environment; broader market weakness for growth/biotech names could compress multiples.
  • Intellectual property, litigation, or competitor innovations (e.g., gene therapy, ASO, mRNA platforms) that challenge market share.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ALNY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.